Open Labelled Passive Controlled Clinical Evaluation of External Application of Himawan Agad as Prophylaxis in Paclitaxel Chemotherapy-Induced Peripheral Neuropathy (PIPN)

Brief SummaryCancer is commonly treated with chemotherapy, but these medicines often cause side effects that reduce a patient’s comfort and quality of life. Paclitaxel, a widely used chemotherapy drug, is very effective against cancers like breast, ovarian, and lung cancer, but it frequently causes peripheral neuropathy a condition marked by tingling, burning, pain, numbness, and loss of sensation in the hands and feet. These symptoms may become severe or long-lasting, forcing doctors to reduce or stop chemotherapy. Himawan Agad, a classical Ayurvedic formulation described in Ashtanga Hridaya, is traditionally indicated for conditions involving burning, pain, inflammation, and Vata-Pitta dominance. When used externally as Himawan Agad Lepa, mixed with honey, it contains herbs known for pain relief, burn-relieving, anti-inflammatory, neuroprotective, and tissue-healing actions. This study is designed as an open-label passive-controlled clinical evaluation to assess the preventive role of Himawan Agad Lepa in patients receiving Paclitaxel chemotherapy. By applying the formulation externally, especially over vulnerable areas like the lower limbs, the therapy aims to reduce the onset and severity of neuropathic symptoms. The study seeks to establish a safe, cost-effective, and integrative Ayurvedic approach for preventing chemotherapy-induced peripheral neuropathy and improving patient comfort and treatment continuity.